Core Insights - Boston Scientific's MedSurg segment is experiencing robust growth, particularly in endoscopy, neuromodulation, and urology, with promising long-term prospects for WATCHMAN devices [1][5][8] - The company's stock has outperformed the industry and S&P 500, with a 33.6% increase over the past year [2] - Strategic acquisitions have significantly contributed to revenue growth, with recent buyouts adding 400 basis points to Q1 sales and driving 18.2% organic revenue growth [6][9] MedSurg Segment Performance - The Endoscopy business is gaining market share due to strong growth in endoluminal surgery and single-use imaging franchises, alongside the AXIOS platform [3] - Urology market share is expanding globally, driven by successful product launches like the TENACIO pump and the LithoVue portfolio [4] - Neuromodulation is also seeing growth, particularly in pain and brain businesses, with expectations for improved growth in deep brain stimulation by 2025 [4] WATCHMAN Device Growth - The WATCHMAN device is gaining momentum as a leading non-pharmacologic alternative to oral anti-coagulants, with a 24% year-over-year sales increase in Q1 2025 [5][8] - The next-generation WATCHMAN FLX and FLX Pro are capturing significant market share [5] Strategic Acquisitions - Recent acquisitions, including Bolt Medical and Cortex, have added valuable products to Boston Scientific's portfolio [6] - The acquisition of Axonics in Q4 2024 has also contributed positively to sales growth [9] Financial Performance - The company has consistently beaten earnings estimates, with an average surprise of 8.79% over the last four quarters [2] - The Zacks Consensus Estimate for 2025 earnings per share is $2.91, with revenues expected to rise by 16.4% to $19.50 billion [11] Currency Exposure - Boston Scientific faces risks from currency fluctuations, with 40% of sales coming from international markets, which could impact revenues by 50 basis points in 2025 [10]

Pump fun's has only one real competitor: Axiom.Weirdly, CT is quiet about it.I missed $HYPE airdrop, but I'm not missing $AXIOM-----Axiom consistently trails Pump on daily fees, often generating more than Solana itself.Backed by YCombinator "Axiom the fastest company in YC history to hit $100m in real top-line revenue"It "took Cursor 12 months to hit same $100m" - @TheOneandOmsyInterestingly, Axiom official X account and co-founders are keeping a very low profile on X with very few posts.Marketing is spread ...

First-in-human trial of AX-0810 will evaluate safety, tolerability, pharmacokinetics, and target engagement in healthy volunteers with initial data expected in Q4 2025Marks the first submitted Clinical Trial Application (CTA) advancing ProQR’s Axiomer™ ADAR-mediated RNA editing platform into clinical development LEIDEN, Netherlands & CAMBRIDGE, Mass., June 26, 2025 (GLOBE NEWSWIRE) -- ProQR Therapeutics NV (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies bas ...

Key Takeaways BSX gains MedSurg share via growth in Endoscopy, Urology and Neuromodulation product lines. MDT expands Surgical Robotics with Hugo RAS, now rolled out across 30 international markets. Both BSX and MDT see growth in emerging markets. Investors are increasingly eyeing the fast-growing MedSurg equipment space, which is projected to witness a compound annual growth rate (CAGR) of 9.54% from 2025 to 2030 (per Grand View Research). Two prominent companies with a strong foothold in this space are ...

are you thinking about using Axiom well before you do you need to watch this video that's because we're about to walk you through everything you need to know to get started on Axiom step by step so you can get the most out of this powerful DeFi trading terminal we'll also share some essential tips and tricks to help you trade safely and efficiently valuable insights you won't find anywhere else so make sure you stick around until the very end my name is Guy let's get started okay before we get going it's im ...

Core Insights - Boston Scientific's Endoscopy business is strategically positioned to benefit from the expanding global endoscopy devices market, which is projected to grow from $28.1 billion in 2022 to $44.1 billion by 2032 at a CAGR of 4.6% from 2023 to 2032 [1] Company Performance - Sales of Endoscopy products reached $673 million in Q1 2025, reflecting a 6% increase both operationally and organically, accounting for 14% of the company's overall revenues [2][8] - The growth in sales is attributed to steady performance across geographies and a diverse product suite, with notable double-digit growth in the AXIOS Stent and Electrocautery Enhanced Delivery System [3][8] - The Endoluminal Surgery franchise also experienced double-digit growth driven by innovative technologies such as OverStitch and MANTIS Clip, indicating strong adoption of advanced endoscopic tools [4] Competitive Landscape - Stryker's Endoscopy segment reported a strong 11.1% increase in U.S. organic sales, driven by double-digit gains in core endoscopy and sports medicine portfolios [5] - Johnson & Johnson, through its subsidiary Ethicon, is a key competitor, focusing on advanced energy-based endoscopic surgery platforms and digital surgery initiatives [6] Stock Performance - Boston Scientific's shares have increased by 27.3% over the past year, outperforming the industry growth of 9.7% and the S&P 500's growth of 11% during the same period [7] Valuation Metrics - The company trades at a forward 12-month price-to-earnings ratio (P/E) of 32.13X, which is above the industry average of 21.33X [9] Earnings Estimates - The Zacks Consensus Estimate for Boston Scientific's earnings has been on the rise over the past 60 days, indicating positive sentiment regarding future performance [11]

New AXIOM model captures mainstream headlines and industry acclaimVANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS; OTCQB: VRSSF) (“VERSES” or the “Company”) a cognitive computing company specializing in next-generation agentic software systems today announced important third-party recognition of its digital-brain architecture, AXIOM, following features in WIRED and Popular Mechanics and public acknowledgement from ARC-AGI benchmark creator François Chollet. WIRED: A ...

Core Viewpoint - NASA and its partners have postponed the Axiom Mission 4 launch schedule and are reassessing the launch date [1] Group 1 - The postponement indicates potential delays in upcoming space missions, which may impact the overall timeline for commercial spaceflight initiatives [1] - The decision to reassess the launch date suggests that NASA is prioritizing safety and thorough evaluation of mission parameters [1]

VERSES new AXIOM model is up to 60% better, 97% more efficient and learns 39 times faster than Google® Deepmind’s DreamerV3 in third-party validated benchmarkVANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- VERSES AI Inc. (CBOE: VERS) (OTCQB: VRSSF) (“VERSES” or the “Company”), a cognitive computing company, today revealed results that it believes mark a significant advancement in artificial intelligence. Their new digital brain architecture, codenamed AXIOM (Active eXpanding Inference with Ob ...

JP Morgan analyst Harlan Sur maintained an Overweight rating on Marvell Technology, Inc. MRVL with a price forecast of $130 on Tuesday.This price forecast is based on Marvell’s strong market leadership in optical connectivity, synergies with its Storage, Networking, and embedded processing franchises, and its solid growth outlook in AI/Networking, Sur asserted.Marvell will report earnings on Thursday, and Sur expects a continued volume ramp of Amazon.Com, Inc. AMZN Trainium 2 ASIC and Alphabet Inc. GOOGL GO ...